Skip to content

Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia

Effects of an Optimized 13-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis (Actlife)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03959995
Acronym
ACTLIFE
Enrollment
27
Registered
2019-05-22
Start date
2019-01-15
Completion date
2020-06-05
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia, Osteoporosis

Brief summary

Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life. Early preventive assessments are very difficult to implement due to the complex hormone-deficiency-induced effects on a large variety of organs and systems with estrogen receptors. In fact, only a few types of interventions have the potential to comprehensively improve the various risk factors and complaints of the menopausal transition. In detail, however, not every form of exercise training or every training protocol is effective for exerting positive effects on selected risk factors. In particular, the training concept for addressing musculoskeletal or cardio-metabolic risk factors differ fundamentally. In several studies, we confirmed the effect of different complex training programs on risk factors of different postmenopausal female cohorts with special consideration of osteoporotic aspects. The training programs applied in this context were characterized by the consistent implementation of recognized training principles and an in general exercise intensity-oriented approach. Recent studies confirmed the effectiveness of this proceeding for women with relevant postmenopausal risk factors including low bone strength. However, the crucial issue of the most effective, feasible and easily customizable training protocol for addressing postmenopausal risk factors remains to be answered, taking into account that the majority of exercise programs were realized in an ambulatory group setting. The aim of the study will be to evaluate the effects of an optimized physical training on risk factors and complaints of (early) postmenopausal women with special consideration of the osseous fracture risk. Note (05.06.2020): Of importance, the intervention has to be cancelled due to COVID-19 lockdown in March 2020 after 13 months of intervention.

Interventions

OTHERHigh Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)

Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.

OTHERWellness

control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Blinding attempt of participants by sham exercise. Outcome assessors were unaware of participant's group status (exercise or control) and were not allowed to ask correspondingly.

Eligibility

Sex/Gender
FEMALE
Age
48 Years to 58 Years
Healthy volunteers
No

Inclusion criteria

* (early)postmenopausal women, ( normal menopause, 1-5 years post) * Osteopenia and osteoporosis at the lumbar spine or femoral neck Bone Mineral Density (BMD) \<-1.0 standard deviation (SD) T-Score, WHO)

Exclusion criteria

* BMD \<-4.0 SD T-Score (BMD threshold for pharmaceutical therapy according to Dachverband Osteologie (DVO) guideline (mandatory for Germany, Austria, Suisse) for woman 50-60 years). * Prevalent clinical, low-trauma fractures * Diseases and drugs with relevant effects on bone and muscle metabolism (e.g. glucocorticoids \>7.5 mg/d or bisphosphonate therapy); individual case assessment * Diseases and drugs with relevant effects on cardiometabolic risk factors (e.g. severe hypertension with corresponding medical therapy); individual case assessment * Severe cardiovascular events (e.g. stroke, coronary infarction) in the past. * Other conditions, diseases that exclude exercise training in a group (≤10 persons).

Design outcomes

Primary

MeasureTime frameDescription
BMD Lumbar Spinefrom baseline to 13 month follow-upBone Mineral Density (BMD) at the lumbar spine region of interest as determined by Dual Energy x-Ray Absorptiometry (DXA)

Secondary

MeasureTime frameDescription
Para-vertebral muscle densityfrom baseline to 13 month follow-upMuscle density at the para-vertebral region as determined by Magnetic Resonance Imaging (MRI)
Mid-thigh muscle densityfrom baseline to 13 month follow-upMuscle density at the mid-thigh region as determined by MRI
Metabolic Syndromefrom baseline to 13 month follow-upMetabolic Syndrome Z-Score according to the Internationale Diabetes Federation (IDF)
Visceral body fatfrom baseline to 13 month follow-upVisceral body fat as determined by Magnetic Resonance Imaging (MRI)
Total body fatfrom baseline to 13 month follow-upTotal body fat as determined by whole body DXA
BMD total Hipfrom baseline to 13 month follow-upBone Mineral Density at the total hip region of interest as determined by DXA
Menopausal complaintsfrom baseline to 13 month follow-upMenopausal complaints as determined by the Menopause Rating Scale (German version. Questionnaire with 11 items; scale from 0 (no complaints/problems) to 4 (very severe complaints/problem)
Maximum leg strengthfrom baseline to 13 month follow-upMaximum isokinetic leg extensor strength as determined by an isokinetic leg press
Total fat ratefrom baseline to 13 month follow-upTotal fat rate as determined by Bio Impedance technique (BIA)
Fat free massfrom baseline to 13 month follow-upFat free mass as determined by BIA
Total Lean Body Massfrom baseline to 13 month follow-upTotal Lean Body Mass as determined by whole body DXA

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026